Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia
PITTSBURGH, Oct. 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. RYZUMVI is...
Covered in this story
Call it yourself
No calls on $VTRS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Viatris →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.